

CITATION REPORT

List of articles citing

Pharmacotherapy in COVID-19; A narrative review for emergency providers

DOI: 10.1016/j.ajem.2020.04.035

American Journal of Emergency Medicine, 2020, 38, 1488-149

Source: <https://exaly.com/paper-pdf/77622409/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
66	Immunotherapeutic approaches to curtail COVID-19. <i>International Immunopharmacology</i> , 2020 , 88, 106924	3.4	29
65	COVID-19 associated complications and potential therapeutic targets. <i>European Journal of Pharmacology</i> , 2020 , 886, 173548	5.3	10
64	Nanoceria as a possible agent for the management of COVID-19. <i>Nano Today</i> , 2020 , 35, 100982	17.9	37
63	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. <i>Canadian Respiratory Journal</i> , 2020 , 2020, 4312519	2.1	16
62	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
61	Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic. <i>Risk Management and Healthcare Policy</i> , 2020 , 13, 2707-2728	2.8	8
60	Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations. <i>Frontiers in Chemistry</i> , 2020 , 8, 584894	5	19
59	Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. <i>Obesity Reviews</i> , 2020 , 21, e13128	10.6	427
58	Is Nanotechnology Helping in the Fight Against COVID-19?. <i>Frontiers in Nanotechnology</i> , 2020 , 2,	5.5	19
57	Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations. <i>Separations</i> , 2020 , 7, 47	3.1	2
56	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <i>Frontiers in Pharmacology</i> , 2020 , 11, 584956	5.6	30
55	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	2
54	Remdesivir Bringing Hope for COVID-19 Treatment. <i>Scientia Pharmaceutica</i> , 2020 , 88, 29	4.3	16
53	Review on therapeutic targets for COVID-19: insights from cytokine storm. <i>Postgraduate Medical Journal</i> , 2021 , 97, 391-398	2	11
52	COVID-19 patients could be at high risk for dry socket. <i>Medical Hypotheses</i> , 2021 , 146, 110462	3.8	3
51	Selective Pressure-Free Treatments for COVID-19. <i>Radiation</i> , 2021 , 1, 18-32		2
50	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. <i>Journal of Microbiology, Immunology and Infection</i> , 2021 , 54, 27-36	8.5	8

49	The Current Understanding and Potential Therapeutic Options to Combat COVID-19. <i>SSRN Electronic Journal</i> ,	1	
48	COVID-19 and Dentistry: An Updated Overview of Dental Perspectives and a Recommended Protocol for Dental Care and Emergency Dental Treatment. <i>Journal of Contemporary Dental Practice</i> , 2021 , 22, 572-586	0.7	2
47	Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak. <i>Bulletin of the National Research Centre</i> , 2021 , 45, 27	3	21
46	Repositioning Adequate Antibiotics to Treat/Cure the Coronavirus Disease 2019 (COVID-19): Current Treatments and Future Directions. <i>The Open Biochemistry Journal</i> , 2021 , 15, 1-19	0.9	2
45	Fluoxetine Can Inhibit SARS-CoV-2 In Vitro. <i>Microorganisms</i> , 2021 , 9,	4.9	21
44	Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 815-825	6.2	1
43	An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses. <i>International Immunopharmacology</i> , 2021 , 92, 107365	5.8	7
42	Safety Review of Herbs and Supplements in Heart Disease, Diabetes, and COVID-19.		
41	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1323-1329	3.3	
40	A Mini Review on Emerging Targets and Approaches for the Synthesis of Anti-viral Compounds: In Perspective to COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021 , 21, 1173-1181	3.2	0
39	Does methylprednisolone affect time to recovery in COVID-19 Pneumonia?. <i>Marmara Medical Journal</i> ,		
38	Pharmacovigilance Activities in the Treatment of COVID-19. 2021 , 41, 93-101		
37	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021 , 120 Suppl 1, S6-S18	3.2	4
36	Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1176, 122768	3.2	10
35	Off Label Medication to Combat COVID-19: Review Results to Date. <i>Coronaviruses</i> , 2021 , 2, 496-506	1.5	
34	Cell therapy strategies for COVID-19: Current approaches and potential applications. <i>Science Advances</i> , 2021 , 7,	14.3	3
33	Clinical and operational impact of rapid point-of-care SARS-CoV-2 detection in an emergency department. <i>American Journal of Emergency Medicine</i> , 2021 , 50, 713-718	2.9	1
32	Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021 , 186, 490-500	7.9	11

31	Impact of COVID-19 disease and its treatment on the development of maxillofacial complications. <i>Advances in Oral and Maxillofacial Surgery</i> , 2021 , 4, 100169		
30	Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 394, 997-1001	3.4	6
29	Experimental Pharmacotherapy for COVID-19: The Latest Advances. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 1-13	3	14
28	Toxicity Studies and Inactivation of SARS-CoV-2 by Povidone-iodine Gel Forming Formulations. 2020 ,		10
27	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. 2020 ,		8
26	Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report. <i>World Journal of Radiology</i> , 2020 , 12, 137-141	2.9	9
25	Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic. <i>Drug Discoveries and Therapeutics</i> , 2021 , 14, 273-281	5	5
24	COVID-19 associated myocarditis: A systematic review. <i>American Journal of Emergency Medicine</i> , 2021 , 51, 150-155	2.9	7
23	Effect of Hydroxychloroquine on Clinical Improvement and Mortality Among Patients with COVID-19 Admitted to Four General Hospitals in Saudi Arabia. 2020 , 2, 13-23		
22	Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2. <i>Anatolian Journal of Cardiology</i> , 2020 , 24, 224-234	0.8	10
21	FARMACOS ANTIMICROBIANOS E ANTIVIRAIS COM POTENCIAL USO TERAPÊUTICO PARA A COVID-19. <i>Infarma: Pharmaceutical Sciences</i> , 2020 , 32, 109-119	0.1	
20	Coronavirus (COVID-19) Symptoms, Treatment, and Recent Medical Challenges to the World: A Review. <i>Khalij-Libya Journal of Dental and Medical Research</i> , 2020 , 4, 23-31	0	
19	An overview of 2019 novel coronavirus COVID-19 pandemic: A review study. <i>Journal of Education and Health Promotion</i> , 2021 , 10, 280	1.4	1
18	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. <i>Drug Development Research</i> , 2021 ,	5.1	3
17	Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 ,	3.1	3
16	Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. <i>European Journal of Pharmacology</i> , 2021 , 913, 174632	5.3	2
15	COVID-19 in India: Current status-prevalence, research area, public health, and primary care. <i>Journal of Public Health and Primary Care</i> , 2021 , 2, 51	0.1	
14	Identification of Bioactive Components in QingFeiPaiDu Decoction for Treatment of COVID-19 by Network Pharmacology. <i>Journal of Exploratory Research in Pharmacology</i> , 2022 , 000, 000-000	0.4	

13	The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.. <i>Brazilian Journal of Infectious Diseases</i> , 2022 , 102328	2.8	0
12	Factores relacionados con la neumonía bacteriana en pacientes con COVID-19 en una unidad de cuidados intensivos de Barranquilla, Colombia. <i>Acta Colombiana De Cuidado Intensivo</i> , 2021 ,	0.1	
11	Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.. <i>Clinical Medicine and Research</i> , 2021 , 19, 179-182	1.4	0
10	Sex-Related Factors in Cardiovascular Complications Associated to COVID-19.. <i>Biomolecules</i> , 2021 , 12,	5.9	2
9	Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. <i>Scientific Reports</i> , 2022 , 12, 4925	4.9	5
8	COVID-19 Crisis, Herbal Medicines, and Natural Products - Concerns and Suggestions. <i>Jundishapur Journal of Natural Pharmaceutical Products</i> , 2022 , In Press,	1.1	
7	A Retrospective Analysis of Treatment of Covid-19 with Favipiravir. <i>Journal of Biomedical and Clinical Research</i> , 2022 , 15, 74-78	0	1
6	Elucidating the pathogenicity, diagnosis, treatment, and prevention of COVID-19: Part I. 2022 , 13, 127		0
5	Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality.		0
4	Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Pre vaccination Stage during the Pandemic in Mexico. 2022 , 2022, 1-6		0
3	Immune responses in mildly versus critically ill COVID-19 patients. 14,		1
2	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. 2023 , 117, 109968		0
1	ACEI or not to ACEI: Review on using ACEI and ARBs on COVID-19 patients: Systemic review.		0